- Report
- October 2024
- 197 Pages
Global
From €3399EUR$3,545USD£2,840GBP
€3776EUR$3,939USD£3,155GBP
- Report
- October 2024
- 181 Pages
Global
From €3399EUR$3,545USD£2,840GBP
€3776EUR$3,939USD£3,155GBP
- Report
- March 2025
- 200 Pages
Global
From €2387EUR$2,490USD£1,995GBP
- Report
- March 2025
- 200 Pages
Global
From €4304EUR$4,490USD£3,597GBP
- Report
- May 2024
- 140 Pages
Global
From €6230EUR$6,499USD£5,206GBP
- Drug Pipelines
- November 2024
- 240 Pages
Global
From €2876EUR$3,000USD£2,403GBP
- Report
- August 2024
- 150 Pages
Global
From €2674EUR$2,789USD£2,234GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €3106EUR$3,240USD£2,595GBP
€3451EUR$3,600USD£2,884GBP
- Report
- July 2023
- 220 Pages
Global
From €1908EUR$1,990USD£1,594GBP
- Report
- July 2021
- 50 Pages
China
From €2493EUR$2,600USD£2,083GBP
- Report
- May 2021
- 50 Pages
China
From €2493EUR$2,600USD£2,083GBP
- Report
- October 2022
- 138 Pages
Global
From €4266EUR$4,450USD£3,565GBP
- Report
- February 2024
- 70 Pages
Iran
From €4554EUR$4,750USD£3,805GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1198EUR$1,250USD£1,001GBP
- Report
- November 2023
- 160 Pages
Global
From €3450EUR$3,599USD£2,883GBP
- Report
- May 2023
- 147 Pages
Global
From €4744EUR$4,949USD£3,964GBP
- Report
- January 2024
- 200 Pages
Global
From €3978EUR$4,150USD£3,324GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4554EUR$4,750USD£3,805GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4554EUR$4,750USD£3,805GBP
- Report
- February 2024
- 70 Pages
India
From €4554EUR$4,750USD£3,805GBP

Sulfonylureas are a class of drugs used to treat type 2 diabetes. They work by stimulating the pancreas to produce more insulin, which helps the body to better process glucose. They are usually taken orally, and are often used in combination with other diabetes medications. Sulfonylureas are generally well-tolerated, but can cause side effects such as hypoglycemia, weight gain, and gastrointestinal upset.
The sulfonylureas market is a subset of the larger diabetes drugs market. It is a competitive market, with a range of products available from different manufacturers. The market is expected to grow in the coming years, driven by increasing prevalence of diabetes and the development of new drugs.
Some of the major companies in the sulfonylureas market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less Read more